Opinion|Videos|May 29, 2024
Key Takeaways in HER2-Mutated NSCLC
The panel concludes the discussion with key takeaways on the evolving treatment landscape in HER2 non–small cell lung cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
SB27, a proposed pembrolizumab biosimilar, met primary end points in both a phase 1 pharmacokinetic and a phase 3 efficacy study.
OS was not improved with sigvotatug vedotin vs docetaxel in patients with pretreated, locally advanced, unresectable, or metastatic nonsquamous NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
2
Frontline Treatment Selection in EGFR-Mutated Non-Small Cell Lung Cancer: Monotherapy Versus Combination Strategies
3
GLP-1 Receptor Agonists, Endocrine Therapy, and Metabolic Health Comprise Holistic Breast Cancer Care
4
Dr Geyer on the FDA Approval of T-DXd Followed by THP for HER2+ Breast Cancer
5